CA Patent

CA3225135A1 — 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof

Assigned to Terran Biosciences Inc · Expires 2023-01-12 · 3y expired

What this patent protects

Described herein are compounds that are derivatives (e.g., prodrugs) of 3,4-Methylenedioxymethamphetamine (MDMA). Also described herein are uses of the compounds provided herein for treating or preventing a disease, disorder, or condition in which an increased level of MDMA is be…

USPTO Abstract

Described herein are compounds that are derivatives (e.g., prodrugs) of 3,4-Methylenedioxymethamphetamine (MDMA). Also described herein are uses of the compounds provided herein for treating or preventing a disease, disorder, or condition in which an increased level of MDMA is beneficial.

Drugs covered by this patent

Patent Metadata

Patent number
CA3225135A1
Jurisdiction
CA
Classification
—
Expires
2023-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Terran Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.